Werewolf Therapeutics released a positive SITC update for WTX-124 showing IL-2 INDUKINE can hide in plain site, H.C. Wainwright analyst Andres Maldonado tells investors in a research note. It’s clear that WTX-124 is exhibiting dose-proportional PK which thus far has yielded low levels of active IL-2, which is responsible for the improvement of the safety profile, the firm says. No change was made to the firm’s Buy rating or $15 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HOWL:
- Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics to present clinical, preclinical data at SITC meeting
- Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
- Werewolf Therapeutics to Participate in Upcoming Investor Conferences